GenKyoTex
Leader in NOX therapies, based on the selective inhibition of NOX enzymes.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
€20.3m Valuation: €32.0m | Acquisition | ||
| Total Funding | 000k | ||
BioMed Partners(exited)
VI Partners(exited)
MP Healthcare Venture Management(exited)
Genticel(exited)
Andera Partners(exited)
Wellington Partners(exited)
NeoMed(exited)
University of Geneva(exited)
Vesalius Biocapital IV(exited)
Edmond de Rothschild Group(exited)
| EUR | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 1 % | (8 %) | 4 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.